Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010 (2010), Article ID 624040, 8 pages
http://dx.doi.org/10.1155/2010/624040
Review Article

Peripheral T-Cell Lymphoma: Review and Updates of Current Management Strategies

1Department of Medical Oncology, The National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610
2Department of Pathology, Singapore General Hospital, Outram Road, Singapore 169608

Received 1 September 2010; Accepted 14 November 2010

Academic Editor: Jorge Enrique Romaguera

Copyright © 2010 Tiffany Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Anderson, J. O. Armitage, and D. D. Weisenburger, “Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations,” Annals of Oncology, vol. 9, no. 7, pp. 717–720, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Gisselbrecht, P. Gaulard, E. Lepage et al., “Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas,” Blood, vol. 92, no. 1, pp. 76–82, 1998. View at Google Scholar · View at Scopus
  3. A. Melnyk, A. Rodriguez, W. C. Pugh, and F. Cabannillas, “Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma,” Blood, vol. 89, no. 12, pp. 4514–4520, 1997. View at Google Scholar · View at Scopus
  4. E. S. Jaffe, “The 2008 WHO classification of lymphomas: implications for clinical practice and translational research,” Hematology, pp. 523–531, 2009. View at Google Scholar · View at Scopus
  5. J. M. Vose, M. Neumann, and M. E. Harris, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Rüdiger, D. D. Weisenburger, J. R. Anderson et al., “Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project,” Annals of Oncology, vol. 13, no. 1, pp. 140–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Y. Au, S. Y. Ma, C. S. Chim et al., “Clinicopathological features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organisation classification scheme: a single center experience of 10 years,” Annals of Oncology, vol. 16, pp. 206–214, 2005. View at Google Scholar
  8. S. T. Lim, S. W. Hee, R. Quek et al., “Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis,” European Journal of Haematology, vol. 80, no. 1, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Dogan, P. Gaulard, E. Jaffe et al., “Angioimmunoblastic T-cell lymphoma,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 309–311, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  10. G. Delsol, B. Failini, H. Müller-Hermelink et al., “Anaplastic large cell lymphoma (ALCL) ALK-positive,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 312–316, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  11. D. Mason, N. Harris, G. Delsol et al., “Anaplastic large cell lymphoma ALK-negative,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 317–319, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  12. S. Pileri, D. Weisenburger, I. Sng et al., “Peripheral T-cell lymphoma, not otherwise specified,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 306–308, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  13. P. G. Isaacson, A. Chott, G. Ott et al., “Enteropathy-associated T-cell lymphoma,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 289–291, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  14. K. Ohshima, E. Jaffe, and M. Kikuchi, “Adult T-cell leukaemia/lymphoma,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 281–284, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  15. P. Gaulard, E. Jaffe, L. Krenacs et al., “Hepatosplenic T-cell lymphoma,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 292–293, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  16. E. Jaffe, P. Gaulard, E. Ralfkiaer et al., “Subcutaneous panniculitis-like T-cell lymphoma,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, pp. 294–295, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  17. L. de Leval, D. S. Rickman, C. Thielen et al., “The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper TFH cells,” Blood, vol. 109, no. 11, pp. 4952–4963, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Fruchart, O. Reman, N. Le Stang et al., “Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study,” Leukemia and Lymphoma, vol. 47, no. 12, pp. 2547–2557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Feeney, S. Horwitz, M. Gönen, and H. Schöder, “Characterization of T-cell lymphomas by FDG PET/CT,” American Journal of Roentgenology, vol. 195, no. 2, pp. 333–340, 2010. View at Publisher · View at Google Scholar
  20. H. Tilly, P. Gaulard, E. Lepage et al., “Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome,” Blood, vol. 90, no. 9, pp. 3727–3734, 1997. View at Google Scholar · View at Scopus
  21. G. Longo, C. Fiorani, S. Sacchi et al., “Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma,” Haematologica, vol. 84, no. 5, pp. 425–430, 1999. View at Google Scholar
  22. M. P. Escalón, N. S. Liu, Y. Yang et al., “Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience,” Cancer, vol. 103, no. 10, pp. 2091–2098, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. R. L. ten Berge, J. J. Oudejans, G.-J. Ossenkoppele et al., “ALK expression in extranodal anaplastic large cell lymphoma layouts systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination,” Journal of Clinical Pathology, vol. 53, no. 6, pp. 445–450, 2000. View at Publisher · View at Google Scholar
  24. M. A. Shipp, D. P. Harrington, J. R. Andersen et al., “A predictive model for aggressive non-Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Gallamini, C. Stelitano, R. Calvi et al., “Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study,” Blood, vol. 103, no. 7, pp. 2474–2479, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Mourad, N. Mounier, J. Brière et al., “Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials,” Blood, vol. 111, no. 9, pp. 4463–4470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Ballester, O. Ramuz, C. Gisselbrecht et al., “Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas,” Oncogene, vol. 25, no. 10, pp. 1560–1570, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Tilly, E. Lepage, B. Coiffier et al., “Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma,” Blood, vol. 102, no. 13, pp. 4284–4289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Pfreundschuh, L. Trümper, M. Kloess et al., “Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL,” Blood, vol. 104, no. 3, pp. 626–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Schmitz, L. Trümper, M. Ziepert et al., “Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group,” Blood, vol. 116, no. 18, pp. 3418–3425, 2010. View at Publisher · View at Google Scholar
  31. Y. L. Peng, H. Q. Huang, XU. B. Lin et al., “Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen,” Ai Zheng, vol. 23, no. 8, pp. 943–946, 2004. View at Google Scholar · View at Scopus
  32. G. S. Falchook, F. Vega, N. H. Dang et al., “Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment,” Annals of Oncology, vol. 20, no. 6, pp. 1080–1085, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Rodríguez, M. D. Caballero, A. Gutiérrez et al., “High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience,” Annals of Oncology, vol. 14, no. 12, pp. 1768–1775, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Yamazaki, U. Sawada, Y. Kura et al., “Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy: a single institution study,” Acta Haematologica, vol. 116, no. 2, pp. 90–95, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Schetelig, S. Fetscher, A. Reichle et al., “Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation,” Haematologica, vol. 88, no. 11, pp. 1272–1278, 2003. View at Google Scholar · View at Scopus
  36. C. Kyriakou, C. Canals, A. Goldstone et al., “High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Rodríguez, E. Conde, A. Gutiérrez et al., “Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group,” European Journal of Haematology, vol. 79, no. 1, pp. 32–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Mercadal, J. Briones, B. Xicoy et al., “Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma,” Annals of Oncology, vol. 19, no. 5, pp. 958–963, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. F. D'Amore, T. Relander, G. Lauritzsen et al., “Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphoma (PTCL): a phase II study of the Nordic Lymphoma Group (NLG),” Blood, vol. 108, p. 123a: abstract 401, 2006. View at Google Scholar
  40. P. Reimer, T. Rüdiger, E. Geissinger et al., “Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: results of a prospective multicenter study,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 106–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Corradini, A. Dodera, F. Zallio et al., “Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogenic transplantation of hematopoietic cells,” Journal of Clinical Oncology, vol. 22, pp. 2172–2176, 2004. View at Google Scholar
  42. S. Le Gouill, N. Milpied, A. Buzyn et al., “Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2264–2271, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. G. Kim, S. K. Sohn, Y. S. Chae et al., “CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 1, pp. 35–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. O. A. O'Connor, S. Horwitz, P. Hamlin et al., “Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4357–4364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. O. A. O'Connor, L. Pinter-Brown et al., “PROPEL: results of the pivotal multi-center, phase 2 study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL),” Journal of Clinical Oncology, vol. 27: abstract 8561, 2009. View at Google Scholar
  46. L. Ginaldi, M. De Martinis, E. Matutes et al., “Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H,” Leukemia Research, vol. 22, no. 2, pp. 185–191, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Gallamini, F. Zaja, C. Patti et al., “Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial,” Blood, vol. 110, no. 7, pp. 2316–2323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. G. Kim, S. K. Sohn, Y. S. Chae et al., “Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 129–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Olsen, M. Duvic, A. Frankel et al., “Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 376–388, 2001. View at Google Scholar · View at Scopus
  50. N. H. Dang, B. Pro, F. B. Hagemeister et al., “Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma,” British Journal of Haematology, vol. 136, no. 3, pp. 439–447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. F. M. Foss, N. N. Sjak-Shie, A. Goy et al., “Phase II study of denileukin diftitox with CHOP chemotherapy in a newly diagnosed PTCL: CONCEPT trial,” Journal of Clinical Oncology, vol. 28, no. 15s, p. 8045, 2010. View at Google Scholar
  52. H. Ueda, H. Nakajima, Y. Hori et al., “FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity,” Journal of Antibiotics, vol. 47, no. 3, pp. 301–310, 1994. View at Google Scholar · View at Scopus
  53. R. Piekarz, J. Wright, R. Frye et al., “Results of a phase 2 NCI multicenter study of Romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL),” Blood, vol. 12, pp. 924–932, 2008, abstract 1567. View at Google Scholar
  54. E. A. Olsen, Y. H. Kim, T. M. Kuzel et al., “Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3109–3115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. R. L. Piekarz, R. Frye, M. Turner et al., “Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5410–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus